Mapping out the competitive landscape for the next generation pharma market
As most pharmaceutical, biotechnology and generics companies have now closed the financial books on 2006, Global Insight has take the opportunity to map out the competitive landscape for 2007-10. With traditional big-hitters - such as Pfizer and Amgen in the USA, AstraZeneca in Europe and Takeda in Japan - faltering at the pipeline stage, which movers and shakers are best positioned to assume the mantle of growth in the global pharmaceutical industry? Perhaps more importantly, how are they doing so? What will be the key catalysts?
- The global pharmaceutical industry is still a growth sector, but only just, says the independent analysis and forecasting company. The 2007-10 period should see continued mid-single-digit annual
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze